Rigel Pharmaceuticals Inc (RIGL)
1.325
-0.02
(-1.12%)
USD |
NASDAQ |
Mar 31, 15:34
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 230.09M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -55.48% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.900 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -2.897 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 86.40% |
News
Headline
Wire
Time (ET)
MT Newswires
03/09 10:17
SA Breaking News
03/08 11:54
PR Newswire
03/08 08:30
MT Newswires
03/07 16:16
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/03/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/03/2023* | -- | Results | Q1 2023 | -- | -0.10 | -- | |
| 03/07/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/07/2023 | -- | Results | Q4 2022 | 0.01 | -0.11 | 109.1% | |
| 11/03/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.11 | -0.14 | 19.07% | |
| 08/02/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/02/2022 | -- | Results | Q2 2022 | -0.08 | -0.12 | 34.13% |
*Estimated Date/Time
Earnings
Profile
| Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |
| URL | https://www.rigel.com |
| Investor Relations URL | https://www.rigel.com/investors |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 03, 2023 (est.) |
| Last Earnings Release | Mar. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 30, 2023.
Fundamentals
| Revenue (TTM) | 120.24M |
| Total Expenses (TTM) | 174.47M |
| Net Income (TTM) | -58.57M |
| Total Assets (Quarterly) | 134.28M |
| Total Liabilities (Quarterly) | 147.90M |
| Shareholders Equity (Quarterly) | -13.62M |
| Cash from Operations (TTM) | -73.76M |
| Cash from Investing (TTM) | 72.78M |
| Cash from Financing (TTM) | 6.55M |
Ratings
Profile
| Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |
| URL | https://www.rigel.com |
| Investor Relations URL | https://www.rigel.com/investors |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 03, 2023 (est.) |
| Last Earnings Release | Mar. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| RIGL Tweets |